Pro-Dex, Inc. logo

PDEX Earnings Date: Feb 4, 2027 (Estimated) — Pro-Dex, Inc.

NASDAQ · Healthcare · Medical Instruments & Supplies

Updated

Price $63.50
Market Cap $203.4M
P/E 14.7
52W Range $28.40 – $77.00
Next Earnings · After close (est.)

When is PDEX's next earnings date?

Pro-Dex, Inc. (PDEX) is expected to report Q2 2027 earnings on Thursday, February 4, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.72 on revenue of $20.5M.

How did PDEX do in its last earnings report?

In its most recent report on Oct 29, 2026 (Q1 2027), Pro-Dex, Inc. posted EPS of $0.92 versus the $0.67 estimate, a beat of 37.3%. Revenue was $20.6M against a $20.4M estimate.

How much does PDEX stock move after earnings?

PDEX beat EPS estimates in 7 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 12.6% (up or down) in the day after earnings.

About Pro-Dex, Inc.

Pro-Dex, Inc. focuses on the development and manufacturing of advanced motorized surgical instruments. These sophisticated tools are supplied globally to original equipment manufacturers (OEMs) in the medical device sector. Their product portfolio features versatile, autoclavable (sterilization-friendly) surgical drivers and shavers, available in both battery-powered and electric models, often equipped with multi-functional capabilities. These instruments are primarily employed in orthopedic, thoracic, and craniomaxillofacial surgical procedures. Beyond its core manufacturing, Pro-Dex also offers expert consulting services, covering engineering, quality assurance, and regulatory compliance. Furthermore, the company manufactures and distributes rotary air motors to various industrial clients. Founded in 1978, Pro-Dex, Inc. maintains its corporate headquarters in Irvine, California.

🤖 AI Earnings Analysis

Pro-Dex’s medical-device sales momentum remains robust, but customer concentration and a shrinking backlog temper confidence in sustainability. Q1 revenue rose 11% year over year to $21 million, while EPS fell to $0.92 from $1.40, making the beat mixed.

AI-generated summary — powered by BigEarnings.

Earnings History

DatePeriodEPS Est.EPS Act.SurpriseRevenueResult1D Δ1W Δ1M Δ
2026-10-29Q1 20270.670.92+37.31%$20.6M✅ Beat———
2026-09-03Q4 20260.670.87+29.85%$20.4M✅ Beat+18.88%+1.71%+5.92%
2026-04-30Q3 20260.621.20+93.55%$19.9M✅ Beat-3.55%+14.52%+33.49%
2026-01-29Q2 20260.590.66+11.86%$18.7M✅ Beat-0.44%-2.42%+17.07%
2025-10-30Q1 20260.501.40+180.00%$18.5M✅ Beat+18.32%+6.40%+22.33%
2025-09-04Q4 20250.470.36-23.40%$17.5M❌ Miss-16.48%-23.08%-25.60%
2025-01-30Q2 20250.380.61+60.53%$16.8M✅ Beat-11.59%-20.05%-16.02%
2024-10-31Q1 20250.290.75+158.62%$14.9M✅ Beat+19.08%+32.50%+57.99%

Showing last 8 quarters.

Revenue by segment & region

By region

FY2016 · $20.2M total · annual

SegmentShareRevenueYoY
North America79.8%$16.1M—
Europe19.0%$3.8M—
Other1.1%$225K—

Source: company filings via FMP. YoY compares the same fiscal period a year earlier.

Related Companies

Learn More

Explore More

Financial data from licensed market-data providers; risk factors from SEC EDGAR filings. AI-powered analysis. Data last updated .